hi and welcome to another edition of your health with Dr Christie my name is Dr Christy Reisinger and today I'm going to give you all an update on a highly discussed medication for diabetes called Manjaro the generic name of this medication is tercepatide this medication is approved for diabetes treatment but also has a wonderful side effect of causing weight loss and I foresee this being approved specifically for weight loss in the coming months Manjaro is similar to my favorite glp-1 Agonist called semaglatide also known as ozympic or wigovi but it also has another medication in
it as well that's in a class of medications called Gip agonists this stands for glucose dependent insulinotropic polypeptide similar to somaglatide Manjaro reduces hemoglobin A1c which is a three-month average of blood sugars by about 2.3 percent but it also leads to Greater weight loss about 10 pounds more weight loss than somaglatide which is really significant and exciting this medication like The glp-1 Agonist is a once a week injection and works by stimulating insulin release making people feel Fuller for longer periods of time and helping the body decrease glucose production but while glp-1 agonists like some
aglotide have been shown to lower cardiovascular risks like heart attacks and strokes the data on Manjaro about this won't be out until 2025 because it's so new on the market and a disappointing finding is that when these injectable medications are stopped patients gain the weight back this is true for ozempic wegovi and probably Manjaro II the reason for this is because these medications are actually hormones that the stomach reduces in response to food to help the body understand when to stop eating and it's felt to be underproduced in people that struggle with their weight so
it would only make sense that when these hormones are stopped these signals to the brain are lost and weight gain will occur but the biggest issue I've had with Manjaro is simply getting it for my patients there's been a supply shortage and of course the cost is outrageous it costs about a thousand dollars a month if insurance doesn't cover it and while patients without diabetes can use the medication for weight loss it won't be covered by insurance for this sole purpose at least at this point it is awaiting FDA approval for weight loss and I'm
hoping that will change in the future if you're interested in using either a glp-1 like somaglitide also known as wegovia or azympic or the glp-1 Gip combo with terzapatide also known as Manjaro and you your health insurance won't cover it call the human resource manager at your company and ask them to consider opting in for coverage of weight loss medications the change for coverage really has to happen at the company that you work for that's providing your health insurance and stay tuned for even more weight loss injectable medications to be coming out in the future
there are others on the horizon which is really exciting thanks for joining me
